(COG ANHL1131) Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Title (COG ANHL1131) Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Principal Investigator Matthew Barth, MD

Study Number 221412

PhaseII/III

Summary For the patients with advanced stage B-Cell NHL/B-AL to test whether adding 6 injections of rituximab to standard LMB chemotherapy regimen improves the EFS compared with LMB chemotherapy alone.

Eligibility Please see ClinicalTrials.gov link above.

For more information about the clinical study go to Clinicaltrial.Gov